Sharing Helps Cure

The Impact of Data Sharing on the Development of innovative Drugs

Dr. med. Katharina Gasser, General Manager
Roche Pharma (Schweiz) AG

31. October 2024

Agenda

Swiss healthcare system	Promoting quality & efficiency	**01**
Life science research in Switzerland	Promotion of innovation, research & development	**02**
Patient	Improved diagnosis and promotion of individual treatment quality	**03**

Pharmaceutical industry is part of the healthcare system

Our interest in the digitalization of the healthcare system

**Digitalization +
Access and use of health data**

**Quality and sustainability in
healthcare**

Our contribution to digitalization
Involvement at various levels

Dialog with politicians & authorities and other partners in the healthcare system

Development of positions and distribution to stakeholders

Public discussion platforms (Roche Forum, Roche Turmgespräche)

Digitalization campaigns "Sharing helps cure"

Interpharma Association - Health Data Ecosystem Task Force

Implementing, testing and driving forward new approaches (e.g. VBHC)

Value =

Outcomes that matter to patients

Cost across full cycle of care

Universitätsspital Basel

Research and development

Health data in pharmaceutical research

> 1 mio. substances

10 000 substances

20 substances

10 molecules

1 molecule

0   5   10   15   20   Jahre

| RESEARCH | PRECLINICAL PHASE | CLINICAL PHASE | PATIENT ACCESS |

Market approval and launch

Temporary approval or official requirements

Local data

→ Relevant for the **short and medium term**

Research & Development

Large data sets

International

→ Access is relevant in the **long term**

Roche

Open dialog and transparency are needed

Sharing data starts with us, but needs all stakeholders

Make health data available for medical research:

Population (n=1006)				
7%	10%	12%	28%	43%

- ■ 1 << I am not prepared to do this at all>>
- ■ 2
- ■ 3
- ■ 4
- ■ 5 << I am fully prepared to do so>>

Trust that health data will be used for medical research in the interests of patients:

	1	2	3	4	5	I don't know
Hospitals	5%	7%	12%	36%	31%	
Universities	5%	7%	21%	37%	29%	1%
Swiss authorities	8%	11%	25%	30%	26%	
Health insurance industry	27%	23%	31%	13%	6%	
Pharmaceutical industry	26%	25%	30%	14%	5%	

- ■ 1 << very low>>
- ■ 2
- ■ 3
- ■ 4
- ■ 5 << very high>>
- ■ I don't know / no answer

Independent survey commissioned by Roche Pharma (Switzerland) Ltd
Pletscher et al. 2022 SMW

6

The patient journey at the core
Silos must be broken up

| Prevention | Early symptoms/ Evaluation | Diagnosis | Early Stages Curative Setting | Metastatic Stages / Palliative Care 1L TX | 2L TX | After care & Monitoring |

| | Patient Identification | Pathology & Testing | Key Early Stage Treatment | Key Metastatic Treatment | | Patient Monitoring & Beyond The Pill Solutions |

Digitalization & data support

Sharing helps cure

My personal wishlist

**Driving digitalization
and breaking down
silos**

Data Governance
Transparency and access to
high-quality data

**Secondary use of
health data**

Patient journeys
Must be able to be mapped
out

**Increased use of digital
healthcare solutions**

**Measurable patient
benefit**
Must become an integral
part of routine practice

Doing now what patients need next